Mark Blumling
Mark Blumling is an Executive in Residence at Patient Square Capital. A passionate advocate of health care and life sciences innovation, Mr. Blumling has devoted his 25+ year career to improving patient health. He currently serves as an Advisor at Goldman Sachs Growth Equity and Adjunct Faculty and Lecturer at Stanford Law School.
Mr. Blumling is the former CEO and Founder of Headlands Research, a KKR-backed clinical research site company (acquired in 2025). He was previously CEO and Co-Founder of Genos, a big data health care technology company (acquired in 2017) and CEO of Relevare Pharmaceuticals, a pharmaceutical company based in San Francisco and Australia. Prior to joining Relevare, Mr. Blumling was Founder and COO of Hyperion Therapeutics (NASDAQ: HPTX; acquired May 2015).
Mr. Blumling received a J.D. from Stanford Law School, an M.Sc. in Economics from the London School of Economics, and a B.A. in Human Biology from Stanford University. He is a Member of the Council on Foreign Relations.